Company type
Limited Corporation
Established
1997
Size
Medium
Employees
100-199
Revenue
41 MDKK
Gross profit
- DKK
Operating Profit (EBIT)
-587,285,000 DKK
Profit for the Year
-570,167,000 DKK
Equity
1,194 MDKK
ad

More financial key figures and analyses?

In Bisbase Premium you get more financial key figures for both companies, groups and industries plus access to exclusive industries complied by experts. You can also create your own analyses! It only takes a minute or so - and it's free!

Rank Profit for the Year

Rank in industry
944/945
"Lowest 10%"
Rank in Denmark
303,195/303,241
"Lowest 10%"

Top management Top 3

Board Top 3

Alf Gunnar Martin Nicklasson 1Chairman of board
Kirsten Aarup Drejer 8Vice chairman
Alain Munoz 1Boardmember

Legal owners Top 3

15-19.99%Van Herk Investments B.V.
5-9.99%Wellington Management Group LLP
0-4.99%Van Herk Management Services B.V.

Rights certificate

Selskabet tegnes af bestyrelsens formand i forening med den administrerende direktør, eller af bestyrelsens formand i forening med et bestyrelsesmedlem, eller af en direktør i forening med 2 bestyrelsesmedlemmer, eller af den administrerende direktør i forening med en direktør eller af den samlede bestyrelse.

Company information based on CVR

NameZealand Pharma A/S
Alternate namesZealand Pharmaceuticals A/S, Connexon A/S, Peptide Probe Technologies A/S, Ppt A/S Show more
CVR20045078
AddressSydmarken 11, 2860 Søborg
IndustryResearch and experimental development on biotechnology [721100]
Webhttp://www.zealandpharma.com
Established01-04-1997 (23 yr)
Company typeLimited Corporation
Number of employees100-199 (CVR)
Advertising protectionNo
AuditorEy Godkendt Revisionspartnerselskab since 02-04-2020
Financial statement period01-01 to 31-12
Listed on stock exchangeYes
Nasdaq OMX Copenhagen ZEAL
Company capital39,734,151 DKK
37,049,690 DKK (12-06-2020 - 17-06-2020)
37,008,195 DKK (26-05-2020 - 11-06-2020)
36,917,324 DKK (15-04-2020 - 25-05-2020)
36,887,952 DKK (26-03-2020 - 14-04-2020)
36,146,136 DKK (20-03-2020 - 25-03-2020)
Articles of assoc. last18-06-2020

Purpose

Selskabets formål er at drive forskning, produktion, handel og dermed beslægtet virksomhed, primært indenfor medicinalbranchen.

Financial Statement

 201920182017
Currency/unit000' DKK000' DKK000' DKK
Revenue
41,333
+215%
13,119
-58%
31,412
+1,697%
Gross Profit
-
-
-
-
-
-
Profit for the Year
-570,167
-
498,516
-
-171,739
-
Equity
1,193,710
+12%
1,066,912
+94%
549,229
+177%
Total Assets
1,540,841
+31%
1,173,621
+91%
615,049
+148%

Map